共 50 条
Management of Knee Osteoarthritis What Internists Need to
被引:13
作者:
Block, Joel A.
[1
]
Cherny, Dmitriy
[1
]
机构:
[1] Rush Univ, Div Rheumatol, Med Ctr, 1611 West Harrison St,Suite 510, Chicago, IL 60612 USA
基金:
美国国家卫生研究院;
关键词:
Osteoarthritis;
Knee pain;
Nerve growth factor;
Placebo effect;
Platelet rich plasma;
PLATELET-RICH PLASMA;
INTRAARTICULAR INJECTION;
RHEUMATOID-ARTHRITIS;
CONTROLLED-TRIAL;
PAIN;
EFFICACY;
TANEZUMAB;
SAFETY;
RISK;
HIP;
D O I:
10.1016/j.mcna.2020.10.005
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Knee osteoarthritis (OA) is a common and morbid condition. No disease-modifying therapies exist; hence the goals of current treatment are to palliate pain and to retain function. OA is significantly influenced by the placebo effect. Nonpharmacologic interventions are essential and have been shown to improve outcomes. Canes, unloading braces, and therapeutic heating/cooling may be valuable. Pharmacotherapy options include topical and oral nonsteroidal anti-inflammatory drugs, duloxetine, and periodic intra-articular glucocorticoids and hyaluronans. Opioids, intra-articular stem cells, and platelet-rich plasma are not recommended. Novel targets such as nerve growth factor are under investigation and may be approved soon for OA pain. © 2020 Elsevier Inc.
引用
收藏
页码:367 / 385
页数:19
相关论文